Nanoliposomal irinotecan-based chemotherapy after regular irinotecan-based chemotherapy in patients with pancreas cancer.

Smith, CJ; Bekaii-Saab, TS; Cook, K; Eiring, R; Halfdanarson, TR; Hanna, MSE; Jin, ZH; Jochum, JA; Ma, WW; Mitchell, JL; Pitot, HC; Jatoi, A

JOURNAL OF CLINICAL ONCOLOGY, 2021; 39 (3):